CD274 and non-small cell lung carcinoma: Moreover, Check-Mate 017 and Check-Mate 057 studies demonstrated that PD-L1 expression is positively associated with greater overall survival in patients treated with Nivolumab that have a NSCLC with ≥50% PD-L1 expression; however, an effective response is still observed in patients with ≥1% PD-L1 expression [25].